Drugs / universal allogeneic anti-CD19/BCMA CAR T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06978738 | May 2025 → May 2027 expected | anti-neutrophil cytoplasmic antibody-associated vasculitis, autoimmune hemolytic anemia, immunoglobulin G4-related sclerosing disease, myasthenia gravis +3 | Changzhou No.2 People's Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | universal allogeneic anti-CD19/BCMA CAR T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06978738 ↗ |
| Known as | UCAR T-cells | “A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells” NCT06978738 ↗ |
| Modality | Cell therapy | “universal allogeneic anti-CD19/BCMA CAR T-cells” NCT06978738 ↗ |